These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23407473)

  • 1. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.
    Huls MH; Figliola MJ; Dawson MJ; Olivares S; Kebriaei P; Shpall EJ; Champlin RE; Singh H; Cooper LJ
    J Vis Exp; 2013 Feb; (72):e50070. PubMed ID: 23407473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
    PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sleeping beauty system to redirect T-cell specificity for human applications.
    Maiti SN; Huls H; Singh H; Dawson M; Figliola M; Olivares S; Rao P; Zhao YJ; Multani A; Yang G; Zhang L; Crossland D; Ang S; Torikai H; Rabinovich B; Lee DA; Kebriaei P; Hackett P; Champlin RE; Cooper LJ
    J Immunother; 2013 Feb; 36(2):112-23. PubMed ID: 23377665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
    Singh H; Huls H; Kebriaei P; Cooper LJ
    Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
    Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
    Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.
    Jin Z; Maiti S; Huls H; Singh H; Olivares S; Mátés L; Izsvák Z; Ivics Z; Lee DA; Champlin RE; Cooper LJ
    Gene Ther; 2011 Sep; 18(9):849-56. PubMed ID: 21451576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transposon and transposase system for human application.
    Hackett PB; Largaespada DA; Cooper LJ
    Mol Ther; 2010 Apr; 18(4):674-83. PubMed ID: 20104209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.
    Singh H; Manuri PR; Olivares S; Dara N; Dawson MJ; Huls H; Hackett PB; Kohn DB; Shpall EJ; Champlin RE; Cooper LJ
    Cancer Res; 2008 Apr; 68(8):2961-71. PubMed ID: 18413766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
    Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
    Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
    Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
    J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.
    Manuri PV; Wilson MH; Maiti SN; Mi T; Singh H; Olivares S; Dawson MJ; Huls H; Lee DA; Rao PH; Kaminski JM; Nakazawa Y; Gottschalk S; Kebriaei P; Shpall EJ; Champlin RE; Cooper LJ
    Hum Gene Ther; 2010 Apr; 21(4):427-37. PubMed ID: 19905893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
    Huang X; Guo H; Kang J; Choi S; Zhou TC; Tammana S; Lees CJ; Li ZZ; Milone M; Levine BL; Tolar J; June CH; Scott McIvor R; Wagner JE; Blazar BR; Zhou X
    Mol Ther; 2008 Mar; 16(3):580-9. PubMed ID: 18227839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
    Mucha M; Štach M; Kaštánková I; Rychlá J; Vydra J; Lesný P; Otáhal P
    Front Immunol; 2024; 15():1415328. PubMed ID: 39192973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.
    Sumiyoshi T; Holt NG; Hollis RP; Ge S; Cannon PM; Crooks GM; Kohn DB
    Hum Gene Ther; 2009 Dec; 20(12):1607-26. PubMed ID: 19689196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.
    Deniger DC; Pasetto A; Tran E; Parkhurst MR; Cohen CJ; Robbins PF; Cooper LJ; Rosenberg SA
    Mol Ther; 2016 Jun; 24(6):1078-1089. PubMed ID: 26945006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.